Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
409 stopped studies mapped to Mature B-Cell Non-Hodgkin Lymphoma and descendants · 88% state a reason
Over the 409 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05022797 | Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS | Phase 2 | terminated | Aug 26, 2021 | Fundacion CRIS de Investigación para Vencer el Cáncer | closed because of low recruitment | Enrollment / accrual |
| NCT03225716 | A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4… | Phase 1 | terminated | Jul 21, 2017 | Dana-Farber Cancer Institute | Sponsor decision to end follow-up early | Sponsor / business decision |
| NCT04995536 | CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of… | Phase 1 | withdrawn | Aug 9, 2021 | City of Hope Medical Center | no accrual | Enrollment / accrual |
| NCT03801525 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and…(ULTRA-V) | Phase 2 / Phase 3 | terminated | Jan 11, 2019 | TG Therapeutics, Inc. | Strategic/Business decision | Sponsor / business decision |
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell… | Phase 1 | terminated | Apr 7, 2017 | Fred Hutchinson Cancer Center | Terminated due to slow enrollment and end of funding | Enrollment / accrual |
| NCT04762160 | SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects… | Phase 2 | terminated | Feb 21, 2021 | Epizyme, Inc. | Decision to terminate EZH-1401 was solely due to company business decision. | Sponsor / business decision |
| NCT03571828 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in… | Phase 1 | terminated | Jun 28, 2018 | Amgen | Amgen decided to discontinue study because of a business decision and not because of safety reasons | Safety / toxicity |
| NCT04115059 | Dasatinib In Waldenström Macroglobulinemia | Phase 1 | terminated | Oct 3, 2019 | Jorge J. Castillo, MD | Lack of efficacy | Efficacy / futility |
| NCT02451111 | Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma | Phase 2 | terminated | May 21, 2015 | Swiss Cancer Institute | The premature termination is based on the decision by the SAKK board on November 14, 2020 due to… | Funding |
| NCT03151057 | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived… | Phase 1 | terminated | May 12, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Safety endpointreached | Safety / toxicity |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT06247540 | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's… | Phase 2 | withdrawn | Feb 8, 2024 | Northwestern University | Funding | Funding |
| NCT05611853 | Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell… | Phase 1 / Phase 2 | terminated | Nov 10, 2022 | BioNova Pharmaceuticals (Shanghai) LTD. | Due to company decision | Sponsor / business decision |
| NCT03684694 | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell… | Phase 1 / Phase 2 | terminated | Sep 26, 2018 | ADC Therapeutics S.A. | Administrative decision | Other (stated, no rule matched) |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or… | Phase 1 | terminated | Nov 4, 2021 | Prelude Therapeutics | Company Decision | Sponsor / business decision |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT04220008 | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the… | Phase 2 | withdrawn | Jan 7, 2020 | M.D. Anderson Cancer Center | No Participants Enrolled | Enrollment / accrual |
| NCT03864419 | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell… | Phase 1 | terminated | Mar 6, 2019 | Fred Hutchinson Cancer Center | Closed per SRC Low Accrual Policy | Enrollment / accrual |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT04828174 | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies | Phase 1 | suspended | Apr 1, 2021 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | The trial was suspended due to the inability to enroll qualified participants | Enrollment / accrual |
| NCT03572634 | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously… | Phase 1 / Phase 2 | terminated | Jun 28, 2018 | Sumitomo Pharma America, Inc. | Given the extensive time projected to conclude the study hypothesis, it is no longer feasible to… | Other (stated, no rule matched) |
| NCT05222438 | Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant | Phase 2 | withdrawn | Feb 3, 2022 | Barbara Ann Karmanos Cancer Institute | No accrual of participants in 18 months | Enrollment / accrual |
| NCT03679624 | Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia | Phase 2 | terminated | Sep 20, 2018 | Weill Medical College of Cornell University | Low accrual | Enrollment / accrual |
| NCT04699461 | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in…(LOTIS-6) | Phase 2 | terminated | Jan 7, 2021 | ADC Therapeutics S.A. | Administrative decision (not due to safety reason) | Safety / toxicity |
| NCT05867030 | Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma | Phase 1 | withdrawn | May 19, 2023 | Innovent Biologics (Suzhou) Co. Ltd. | Development strategy adjustment | Sponsor / business decision |
| NCT02957019 | A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine… | Phase 1 / Phase 2 | terminated | Nov 7, 2016 | Philogen S.p.A. | Slow progression due to difficulties in finding eligible patients. Competitive clinical trials with… | Other (stated, no rule matched) |
| NCT02204982 | Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously…(DYNAMO + R) | Phase 3 | terminated | Jul 31, 2014 | SecuraBio | Sponsor is focusing on studies which can enable registration of duvelisib | Other (stated, no rule matched) |
| NCT02391545 | A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With… | Phase 1 / Phase 2 | terminated | Mar 18, 2015 | SecuraBio | Sponsor is focusing on studies which can enable registration of duvelisib. | Other (stated, no rule matched) |
| NCT04692155 | Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2…(CHOP U2) | Phase 1 / Phase 2 | terminated | Dec 31, 2020 | University of Alabama at Birmingham | FDA hold | Other (stated, no rule matched) |
| NCT03884972 | Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or… | Phase 1 | withdrawn | Mar 21, 2019 | M.D. Anderson Cancer Center | Request by sponsor due to no enrollment of participants on study | Enrollment / accrual |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT04231734 | Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma | N/A | withdrawn | Jan 18, 2020 | Weill Medical College of Cornell University | Low accrual | Enrollment / accrual |
| NCT03229382 | Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular…(OPERA-PLRG10) | Phase 2 | terminated | Jul 25, 2017 | Polish Lymphoma Research Group | Very slow recruitment due to lack of relapse in the observed group of patients | Enrollment / accrual |
| NCT02536300 | Dose Optimization Study of Idelalisib in Follicular Lymphoma | Phase 3 | terminated | Aug 31, 2015 | Gilead Sciences | Gilead has made the decision to close the study due to enrollment challenges | Enrollment / accrual |
| NCT03121677 | Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma | Phase 1 | terminated | Apr 20, 2017 | Washington University School of Medicine | Vaccine manufacturing has been suspended | Drug supply |
| NCT02134782 | Yoga Fatigue Study | N/A | terminated | May 9, 2014 | The Hospital for Sick Children | The study was closed early for poor accrual when 125/210 planned participants had been enrolled and… | Enrollment / accrual |
| NCT03828448 | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve… | Phase 2 | terminated | Feb 4, 2019 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT05144347 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | Phase 1 | terminated | Dec 3, 2021 | Exelixis | Due to Sponsor reasons. | Other (stated, no rule matched) |
| NCT05604417 | Zandelisib + Tazemetostat in R/R Follicular Lymphoma | Phase 1 / Phase 2 | withdrawn | Nov 3, 2022 | Jacob Soumerai, MD | Termination of Zandelisib clinical development globally | Other (stated, no rule matched) |
| NCT05934097 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | Phase 1 | withdrawn | Jul 6, 2023 | Fate Therapeutics | This study was withdrawn (Sponsor decision). | Sponsor / business decision |
| NCT04156828 | Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory… | Phase 1 | terminated | Nov 8, 2019 | University of Washington | Terminated due to low accrual | Enrollment / accrual |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients… | Early Phase 1 | terminated | Sep 5, 2017 | Rutgers, The State University of New Jersey | Lack of enrollment | Enrollment / accrual |
| NCT02588456 | Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In… | Phase 1 | terminated | Oct 27, 2015 | University of Pennsylvania | This study was terminated due to lack of efficacy | Efficacy / futility |
| NCT02640209 | Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen… | Early Phase 1 | terminated | Dec 28, 2015 | University of Pennsylvania | Study is terminated due to administrative reasons. | Other (stated, no rule matched) |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid… | Phase 1 / Phase 2 | terminated | May 12, 2015 | Asana BioSciences | Business decision | Sponsor / business decision |
| NCT05152459 | Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or… | Phase 1 / Phase 2 | withdrawn | Dec 9, 2021 | City of Hope Medical Center | Feasibility | Other (stated, no rule matched) |
| NCT03850028 | Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution… | N/A | withdrawn | Feb 21, 2019 | University Medical Center Groningen | Closed prematurely because the accrual was not achieved | Enrollment / accrual |
| NCT02914938 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Phase 1 | terminated | Sep 26, 2016 | MEI Pharma, Inc. | discontinuation of zandelisib program | Other (stated, no rule matched) |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | Phase 1 | terminated | Mar 3, 2015 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT03999658 | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected… | Phase 2 | withdrawn | Jun 27, 2019 | Sorrento Therapeutics, Inc. | Sorrento Therapeutics filed for chapter 11 bankruptcy. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 13, 2024source: clinicaltrials